Do Telehealth Abortion Appointments Pose a Risk?

Do Telehealth Abortion Appointments Pose a Risk?

( – Telemedicine abortion startup Abortion on Demand (AOD) currently offers services in more than 20 states. Never satisfied, Democrats and Biden administration officials apparently want to enable a nationwide system for the medically dubious practice of remotely enabling the procedure.

On April 12, the Food and Drug Administration (FDA) announced it temporarily lifted the in-person dispensing requirement for Mifeprex (mifepristone), a prescription drug used to induce abortions chemically. On May 7, it indicated it would conduct a review of the Risk Evaluation and Mitigation Strategies (REMS) underlying the restriction on telehealth and online distribution of Mifeprex, otherwise known as the “morning-after pill.”

On August 17, more than 70 House Democrats introduced a resolution demanding the FDA only consider information “grounded in science” based on “available medical evidence” when considering reinstating the in-person requirement.

The Democrats cited a claim by the American College of Obstetricians and Gynecologists that REMS restrictions on Mifeprex had “no medical basis.” However, the science isn’t clear regarding the drug’s safety.

Supporters of the proposition of distributing Mifeprex through the mail under the supervision of certified medical professionals point to a couple of recent studies. However, neither study followed normal protocols, leaving serious questions regarding the drug’s safety when distributed through telehealth companies.

Additionally, a recent study by Kevin Duffy showed a 54% increase in emergency calls and a 19% rise in ambulance responses involving individuals after using chemical abortion medication.

Democrats are correct to the extent they call on science-based medical decisions when determining the future of telehealth services. However, it’s critical that the FDA only consider studies using standard protocols.

Copyright 2021,